Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy

Nanotechnology

Volumn 22, Issue 26, 2011, Pages

  Paraskar, Abhimanyu ^a   Soni, Shivani ^a   Basu, Sudipta ^a   Amarasiriwardena, Chitra J ^b,c   Lupoli, Nicola ^b,c   Srivats, Shyam ^a   Roy, Rituparna Sinha ^a   Sengupta, Shiladitya ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR EFFICACY; ATTRACTIVE SOLUTIONS; BIODISTRIBUTIONS; BREAST CANCER MODELS; CANCER CELLS; CIS-PLATIN; COORDINATE BONDS; IN-VIVO; NEPHROTOXICITY; PH-DEPENDENT;

BUTENES; CHEMOTHERAPY; DISEASES; EXPERIMENTAL MINERALOGY; GLYCOLS; NANOPARTICLES; PLATINUM; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

PLATINUM COMPOUNDS;

ANTINEOPLASTIC AGENT; CISPLATIN; MACROGOL DERIVATIVE; NANOPARTICLE; POLYELECTROLYTE 60; POLYMER;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; KIDNEY; METHODOLOGY; MOUSE; NANOTECHNOLOGY; NEOPLASM; ORGAN SIZE; PATHOLOGY; SPLEEN; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FLOW CYTOMETRY; HUMANS; KIDNEY; MICE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; ORGAN SIZE; POLYETHYLENE GLYCOLS; POLYMERS; SPLEEN; TREATMENT OUTCOME;

EID: 79957856845     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/22/26/265101     Document Type: Article

References (18)

1. Kelland L 2007 The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 573
2. Jamieson E R and Lippard S J 1999 Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99 2467
3. Leong C O, Vidnovic N, DeYoung M P, Sgroi D and Ellisen L W 2007 The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J. Clin. Invest. 117 1370
4. Madias N E and Harrington J T 1978 Platinum nephrotoxicity Am. J. Med. 65 307
5. Hongo A, Seki S, Akiyama K and Kudo T 1994 A comparison of invitro platinum-DNA adduct formation between carboplatin and cisplatin Int. J. Biochem. 26 1009
6. Knox R J, Friedlos F, Lydall D A and Roberts J J 1986 Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA Cancer Res. 46 1972
7. Go R S and Adjei A A 1999 Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J. Clin. Oncol. 17 409
8. Choi H S, Liu W, Misra P, Tanaka E, Zimmer J P, Itty Ipe B, Bawendi M G and Frangioni J V 2007 Renal clearance of quantum dots Nat. Biotechnol. 25 1165
9. Moghimi S M, Hunter A C and Murray J C 2001 Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 283
10. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas A G and Ithakissios D S 2002 PLGA-mPEG nanoparticles of cisplatin: invitro nanoparticle degradation, invitro drug release and invivo drug residence in blood properties J. Control. Release 79 123
11. Fujiyama J, Nakase Y, Osaki K, Sakakura C, Yamagishi H and Hagiwara A 2003 Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application J. Control. Release 89 397
12. White S C, Lorigan P, Margison G P, Margison J M, Martin F, Thatcher N, Anderson H and Ranson M 2006 Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer Br. J. Cancer 95 822
13. Haxton K J and Burt H M 2009 Polymeric drug delivery of platinum-based anticancer agents J. Pharm. Sci. 98 2299
14. Lin X, Zhang Q, Rice J R, Stewart D R, Nowotnik D P and Howell S B 2004 Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models Eur. J. Cancer 40 291
15. Dhar S, Gu F X, Langer R, Farokhzad O C and Lippard S J 2008 Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl Acad. Sci. USA 105 17356
16. Paraskar A S et al 2010 Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy Proc. Natl Acad. Sci. USA 107 12435
17. Davies M S, Berners-Price S J and Hambley T W 2000 Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA Inorg. Chem. 39 5603
18. Shawver L K, Slamon D and Ullrich A 2002 Smart drugs: tyrosine kinase inhibitors in cancer therapy Cancer Cell 1 117